 trial doxorubicin bisantren mitoxantron advanc breast cancer southwest oncolog group studi women metastat breast cancer doxorubicin patient bisantren patient mitoxantron patient dose week cross-ov design rel efficaci toxic elig patient previou chemotherapi regimen patient estrogen receptor posit endocrin therapi patient assess respons assess toxic effect median age year premenopaus perimenopaus viscer domin diseas present patient ninety-seven percent patient disease-fre interv diagnosi first recurr year respons rate doxorubicin bisantren mitoxantron median time treatment failur day doxorubicin day bisantren day mitoxantron logrank median surviv day doxorubicin day bisantren day mitoxantron logrank surviv year similar agent respons patient respons patient patient mitoxantron patient toxic discontinu therapi common doxorubicin discontinu therapi due request cardiotox major dose-limit toxic effect agent nausea vomit mucos alopecia sever doxorubicin congest heart failur patient doxorubicin patient bisantren patient mitoxantron decreas left ventricular eject fraction moder alexand grade chang common patient doxorubicin doxorubicin-tr patient bisantrene-tr patient mitoxantrone-tr patient studi bisantren mitoxantron modest activ metastat breast carcinoma activ doxorubicin agent cost increas toxic